PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1631723
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1631723
Global Prostate Health Market Size Study, by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx)) and Regional Forecasts 2022-2032
The global Prostate Health Market is valued at approximately USD 37.78 billion in 2023 and is projected to grow at an impressive compound annual growth rate (CAGR) of 9.00% during the forecast period from 2024 to 2032. This robust expansion is attributed to the increasing prevalence of prostate-related disorders, coupled with advancements in diagnostic and therapeutic technologies. Prostate health has emerged as a pivotal area in medical research, with innovative treatments like PARP inhibitors and targeted cytotoxic drugs reshaping the landscape for prostate cancer care.
The market's growth trajectory is underpinned by the rising adoption of minimally invasive therapies and the introduction of OTC medications, enhancing accessibility for benign prostate hyperplasia (BPH) and prostatitis patients. Prescription-based treatments, including Tamsulosin and 5 Alpha Reductase inhibitors, remain dominant, addressing critical patient needs with precision. However, challenges such as regulatory complexities and cost barriers may temper growth. Nonetheless, the surge in research and development investments is expected to offset these challenges by catalyzing innovative therapeutic approaches.
Regionally, North America continues to lead the Prostate Health Market, driven by its robust healthcare infrastructure, high awareness levels, and significant investments in oncology research. Europe closely follows, benefiting from government initiatives aimed at enhancing prostate health management and increasing access to advanced treatments. Meanwhile, the Asia-Pacific region is anticipated to exhibit the fastest growth, fueled by rising healthcare expenditures, a growing geriatric population, and improving diagnostic facilities in emerging economies like China and India.
Major market players included in this report are:
- Pfizer Inc.
- Novartis AG
- GlaxoSmithKline plc
- Merck & Co., Inc.
- AstraZeneca
- AbbVie Inc.
- Bayer AG
- Sanofi
- Boehringer Ingelheim
- Roche Holding AG
- Ipsen
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Cipla Ltd.
The detailed segments and sub-segment of the market are explained below:
By Disease Indication
- Prostate Cancer
- PARP Inhibitors
- Cytotoxic Drug
- Benign Prostate Hyperplasia (BPH)
- Tamsulosin
- 5 Alpha Reductase
- Prostatitis
- OTC
- Prescription (Rx)
By Region
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Comprehensive market estimates and forecasts for 10 years from 2022 to 2032.
- Annualized revenues and detailed regional analysis for each market segment.
- Geographical insights with country-level analyses for major regions.
- Competitive landscape profiling major players and their strategic initiatives.
- Actionable recommendations for market strategies and opportunities.
Table of Contents
Chapter 1. Global Prostate Health Market Executive Summary
- 1.1. Global Prostate Health Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Disease Indication
- 1.3.1.1. Prostate Cancer
- 1.3.1. By Disease Indication
PARP Inhibitors
Cytotoxic Drug
- 1.3.1.2. Benign Prostate Hyperplasia (BPH)
Tamsulosin
5 Alpha Reductase
- 1.3.1.3. Prostatitis
- 1.3.1.4. OTC
- 1.3.1.5. Prescription (Rx)
- 1.3.2. By Region
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Prostate Health Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory Frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Prostate Health Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Increasing Prevalence of Prostate-Related Disorders
- 3.1.2. Advancements in Diagnostic and Therapeutic Technologies
- 3.1.3. Rising Adoption of Minimally Invasive Therapies
- 3.2. Market Challenges
- 3.2.1. Regulatory Complexities
- 3.2.2. Cost Barriers
- 3.3. Market Opportunities
- 3.3.1. Surge in Research and Development Investments
- 3.3.2. Development of Innovative Therapeutic Approaches
- 3.3.3. Expansion into Emerging Economies
Chapter 4. Global Prostate Health Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunities
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Prostate Health Market Size & Forecasts by Disease Indication 2022-2032
- 5.1. Segment Dashboard
- 5.2. Global Prostate Health Market: Disease Indication Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Prostate Cancer
- 5.2.1.1. PARP Inhibitors
- 5.2.1.2. Cytotoxic Drug
- 5.2.2. Benign Prostate Hyperplasia (BPH)
- 5.2.2.1. Tamsulosin
- 5.2.2.2. 5 Alpha Reductase
- 5.2.3. Prostatitis
- 5.2.4. OTC
- 5.2.5. Prescription (Rx)
- 5.2.1. Prostate Cancer
Chapter 6. Global Prostate Health Market Size & Forecasts by Region 2022-2032
- 6.1. North America Prostate Health Market
- 6.1.1. U.S. Prostate Health Market
- 6.1.1.1. Disease Indication Breakdown Size & Forecasts, 2022-2032
- 6.1.1.2. Application Breakdown Size & Forecasts, 2022-2032
- 6.1.2. Canada Prostate Health Market
- 6.1.1. U.S. Prostate Health Market
- 6.2. Europe Prostate Health Market
- 6.2.1. UK Prostate Health Market
- 6.2.2. Germany Prostate Health Market
- 6.2.3. France Prostate Health Market
- 6.2.4. Spain Prostate Health Market
- 6.2.5. Italy Prostate Health Market
- 6.2.6. Rest of Europe Prostate Health Market
- 6.3. Asia-Pacific Prostate Health Market
- 6.3.1. China Prostate Health Market
- 6.3.2. India Prostate Health Market
- 6.3.3. Japan Prostate Health Market
- 6.3.4. Australia Prostate Health Market
- 6.3.5. South Korea Prostate Health Market
- 6.3.6. Rest of Asia Pacific Prostate Health Market
- 6.4. Latin America Prostate Health Market
- 6.4.1. Brazil Prostate Health Market
- 6.4.2. Mexico Prostate Health Market
- 6.4.3. Rest of Latin America Prostate Health Market
- 6.5. Middle East & Africa Prostate Health Market
- 6.5.1. Saudi Arabia Prostate Health Market
- 6.5.2. South Africa Prostate Health Market
- 6.5.3. Rest of Middle East & Africa Prostate Health Market
Chapter 7. Competitive Intelligence
- 7.1. Key Company SWOT Analysis
- 7.1.1. Pfizer Inc.
- 7.1.2. Novartis AG
- 7.1.3. GlaxoSmithKline plc
- 7.2. Top Market Strategies
- 7.3. Company Profiles
- 7.3.1. Pfizer Inc.
- 7.3.1.1. Key Information
- 7.3.1.2. Overview
- 7.3.1.3. Financial (Subject to Data Availability)
- 7.3.1.4. Product Summary
- 7.3.1.5. Market Strategies
- 7.3.2. Novartis AG
- 7.3.3. GlaxoSmithKline plc
- 7.3.4. Merck & Co., Inc.
- 7.3.5. AstraZeneca
- 7.3.6. AbbVie Inc.
- 7.3.7. Bayer AG
- 7.3.8. Sanofi
- 7.3.9. Boehringer Ingelheim
- 7.3.10. Roche Holding AG
- 7.3.11. Ipsen
- 7.3.12. Teva Pharmaceutical Industries Ltd.
- 7.3.13. Sun Pharmaceutical Industries Ltd.
- 7.3.14. Dr. Reddy's Laboratories Ltd.
- 7.3.15. Cipla Ltd.
- 7.3.1. Pfizer Inc.
Chapter 8. Research Process
- 8.1. Research Process
- 8.1.1. Data Mining
- 8.1.2. Analysis
- 8.1.3. Market Estimation
- 8.1.4. Validation
- 8.1.5. Publishing
- 8.2. Research Attributes
